Arcellx Q2 Revenue Misses Estimates, Adjusted EPS Beats Consensus

Arcellx's Q2 revenue of $7.55 mln missed analyst expectations, while adjusted EPS beat consensus. The biotech firm ended Q2 with $538 mln cash, funding expected into 2028. Arcellx plans to launch anito-cel in 160 US centers in 2026 and expects cash reserves to fund operations into 2028. The company aims to meet physician supply expectations for anito-cel and will share longer-term iMMagine-1 data later in 2025.

Arcellx Inc. (NASDAQ: ACLX), a clinical-stage biotechnology company, reported its second-quarter 2025 financial results, revealing a significant drop in revenue and a beat in earnings per share (EPS). The company's Q2 revenue of $7.55 million missed analyst expectations by $6.05 million, falling short of the consensus estimate of $13.60 million [1]. Despite the revenue miss, adjusted EPS for the quarter came in at -$0.94, beating the consensus estimate of -$1.02 [1].

Arcellx ended the quarter with $538 million in cash and cash equivalents, which the company expects to fund its operations through 2028 [2]. The biotech firm also announced plans to launch its anito-cel therapy in 160 US centers in 2026, subject to FDA approval, and aims to meet physician supply expectations for the treatment [2].

The company's research and development expenses decreased by $3.4 million to $37.6 million, while general and administrative expenses increased by $7.3 million to $28.7 million [2]. The net loss for the quarter was $52.8 million, compared to $27.2 million in the same period last year [2].

Arcellx also presented positive preliminary data for its Phase 2 pivotal iMMagine-1 study of anito-cel in patients with relapsed or refractory multiple myeloma (RRMM). The study showed a 97% overall response rate (ORR) and a 68% complete response/stringent complete response (CR/sCR) rate [2]. Additionally, the company received FDA clearance for its IND application for ACLX-004 targeting CD33 and CD123 utilizing its ARC-SparX platform [2].

Analysts remain optimistic about Arcellx's prospects, with the average analyst rating on the shares being "buy" and no "hold" or "sell" recommendations [1]. The median 12-month price target for Arcellx is $113.50, about 37.7% above its August 6 closing price of $70.67 [1].

References:
[1] Reuters. (2025). Arcellx Q2 revenue drops and misses analyst expectations, per LSEG data. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_PLX0118C4:0-biotech-firm-arcellx-s-q2-revenue-misses-estimates/
[2] Yahoo Finance. (2025). Arcellx provides second-quarter 2025 financial results. Retrieved from https://finance.yahoo.com/news/arcellx-provides-second-quarter-2025-200000005.html